Related Experiment Video
Updated: Jan 20, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
Are patients in haemodialysis good candidates for immunotherapy treatment?
Amaya B Fernandez-Diaz1, Alberto J Cunquero-Tomas1, Adrian Garcia-Medina2
1Medical Onoclogy Service.
The effectiveness and safety of nivolumab, an anti-programmed cell death protein 1 mAbmonoclonal antibody, in patients with renal replacement therapy is unclear, with limited evidence supporting its usefulness in this context. Therefore, we report a case of recurrent metastatic melanoma in a patient on haemodialysis successfully treated with nivolumab. As seen in patients without renal impairment, significant regression of the lesions was observed after 8 weeks of treatment, reaching complete clinical response after 4 months. During follow-up, no dose adjustment, delay, or treatment suspension due to toxicity were required.
The effectiveness and safety of nivolumab, an anti-programmed cell death protein 1 mAbmonoclonal antibody, in patients with renal replacement therapy is unclear, with limited evidence supporting its usefulness in this context. Therefore, we report a case of recurrent metastatic melanoma in a patient on haemodialysis successfully treated with nivolumab. As seen in patients without renal impairment, significant regression of the lesions was observed after 8 weeks of treatment, reaching complete clinical response after 4 months. During follow-up, no dose adjustment, delay, or treatment suspension due to toxicity were required.
Related Concept Videos
Tumor Immunotherapy
06:51Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
08:06Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
04:22Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
03:10Microscopic Cyst Resection for the Treatment of Patients Diagnosed with Epididymal Cyst
16:56Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

